Overview

Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients

Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to evaluate after 4 to 6 months the effects of a GLP-1 analog treatment on psoriatic skin lesions in patients with type 2 diabetes.
Phase:
N/A
Details
Lead Sponsor:
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Treatments:
Exenatide
Glucagon
Glucagon-Like Peptide 1
Liraglutide